Overview | Minodronate, chemical name 1-hydroxy-2-[(imidazo [1, 2-A] pyridin-3-yl] ethylidene-1, 1-diphosphonic acid is a novel heterocyclic bisphosphonic acid compound developed by Yamanaka, Japan, for the treatment of hypercalcemia caused by osteoporosis and malignant tumors, its bone resorption inhibiting activity is 2 times, 10 times and 100 times that of incadronate disodium, alendronate sodium and pamidronate disodium, respectively. This product has a significant benefit in the incidence of spinal fractures, while there is a great reduction in gastrointestinal side effects, has now been identified as an effective anti-osteoporosis new drug to prevent fractures. The research and development of the drug will undoubtedly provide a safer, more effective and convenient treatment for patients with clinical diseases, and will produce good social and economic benefits after marketing. |
Application | Mino phosphate impurity 3 is an impurity produced during the synthesis of Mino phosphonic acid, reaction with P-toluenesulfonic acid and 2-aminopyridine ethyl 2-(imidazo [1,2-a] pyridin-3-yl) acetate can be prepared. |
preparation | (E) -4, 4-dimethoxy-2-butenoic acid ethyl ester (Mino phosphate impurity 3) preparation: add 120g of g2, 2-methoxyacetaldehyde and 4L of cyclohexane into a four-necked bottle, add g of anhydrous potassium carbonate under stirring, and stir for 1H. 500ml of triethyl phosphonoacetate was added dropwise and reacted for 6H. At the end of the reaction, 1.5L of water was added to the reaction solution for liquid separation. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain a colorless oily liquid, which was distilled under reduced pressure, there was obtained 3150G of Mino phosphoric acid impurity as a colorless oil in a yield of 71%. |